

Agrisera

This product is for research use only (not for diagnostic or therapeutic use)

contact: support@agrisera.com

Agrisera AB | Box 57 | SE-91121 Vännäs | Sweden | +46 (0)935 33 000 | www.agrisera.com

Product no **AS13 2716**

mAB-M | Mouse anti-human Abeta protein (3-10) region, oligomer-specific (clone 2D10.F6)

Product information


Immunogen	synthetic peptide chosen from human Abeta protein (3-10) region, oligomer specific
Host	Mouse
Clonality	Monoclonal
Subclass/isotype	IgG1, kappa light chain, (clone number 2D10.F6)
Purity	Affinity purified in PBS pH 7.4, no preservatives
Format	Lyophilized
Quantity	50 µg
Reconstitution	For reconstitution add 50 µl of sterile water.
Storage	For short time storage please add sodium azide and store at +4°C. For long time storage store lyophilized/reconstituted at -20°C; once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please, remember to spin tubes briefly prior to opening them to avoid any losses that might occur from lyophilized material adhering to the cap or sides of the tubes.
Additional information	Immunolocalization: human tissue was paraffin-embedded and sectioned. De-waxed and rehydrated in an ethanol gradient. Antigens were retrieved in sodium citrate buffer (pH 6) at 95°C for 1 h. The tissue sections were separately incubated for 1 h at RT with primary antibody and antibody binding was visualized with IgG Peroxidase Reagent Kit. This antibody is specific for human Amyloid-Beta oligomers.

Application information

Recommended dilution	10 µg/ml (IL), 1-2 µg/ml (Dot), 2-4 µg/ml (ELISA capture)
Expected apparent MW	4.5 kDa
Confirmed reactivity	Human
Not reactive in	No confirmed exceptions from predicted reactivity are currently known.
Additional information	Due to location of antigen used to elicit this antibody in 3-10 region, it should bind to full length APP. For high resolution images, please visit the specific product page at www.agrisera.com
Selected references	Meilandt et al. (2019) . Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ. <i>Alzheimers Res Ther.</i> 2019 Dec 1;11(1):97. doi: 10.1186/s13195-019-0553-5. Brännström et al. (2014) . A Generic Method for Design of Oligomer-Specific Antibodies. <i>PLoS ONE</i> . DOI: 10.1371/journal.pone.0090857.

application examples

dot blot



Dot blot reaction of the binding capacity of mAB-M to fibrils, monomers and oligomers. Equal amounts of each sample were spotted on a

Agrisera


This product is **for research use only** (not for diagnostic or therapeutic use)

contact: support@agrisera.com

Agrisera AB | Box 57 | SE-91121 Vännäs | Sweden | +46 (0)935 33 000 | www.agrisera.com

nitrocellulose membrane and then dried. The membrane was blocked with 5% non-fat milk before incubated for 1 h with anti-mAB-M (25nM) and then with secondary antibody, anti-mouse HRP-conjugated (1:1500). The membrane was washed with PBS containing 0.25% Tween-20 before detection using ECL prime (GE Healthcare).

Immunolocalization



IHC used to illustrate the lack of binding of mAB-M to plaques. Tissue sections from the human AD hippocampus were de-waxed and rehydrated in ethanol and then incubated with AS08 357 (A) and mAB-M(B) at RT for 1h. The immunoreactivity was detected with the anti-mouse Peroxidase Reagent Kit (ImmPRESS, Vector Laboratories, Inc.) and then developed using the ImmPACT AEC Peroxidase Substrate kit (Vector Laboratories, Inc.).